Visualization and analysis tool for drug delivery system

• US 10,583,249 B2
• Filed: 01/20/2017
• Issued: 03/10/2020
• Est. Priority Date: 02/05/2016
• Status: Active Grant

• Current Assignee: LifeScan IP Holdings, LLC
• Original Assignee: LifeScan IP Holdings, LLC
• Inventors: Finan, Daniel, Vereshchetin, Pavel
• Primary Examiner(s): Mendez, Manuel A
• Application Number:
  US15/411,117
• Publication Number:
  US 20170224920A1
• Time in Patent Office: 1,145 Days
• CPC Class Codes: A61M 2205/3553 remote, e.g. between patient's home and doctor's office
• CPC Class Codes: A61M 2205/3584 using modem, internet or bluetooth
• CPC Class Codes: A61M 2205/52 with memories providing a history of measured variating parameters of apparatus or patient
• CPC Class Codes: A61M 2230/005 Parameter used as control input for the apparatus
• CPC Class Codes: A61M 2230/201 Glucose concentration
• CPC Class Codes: A61M 5/14244 adapted to be carried by the patient, e.g. portable on the body
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: G16H 20/17 delivered via infusion or injection
• CPC Class Codes: G16H 40/63 for local operation
• CPC Class Codes: G16H 40/67 for remote operation
• CPC Class Codes: G16H 50/70 for mining of medical data, e.g. analysing previous cases of other patients

Abstract

A visualization and analysis tool is provided for an insulin delivery system, such as an artificial pancreas, in which insulin is delivered based upon a system algorithm using a pump that is patient controllable in order to adjust insulin delivery relative to a baseline delivery rate; e.g., pre-set basal rate and a sensor for measuring glucose levels. The tool is configured with a controller of the system to detect and log events that are based on differences between actual insulin delivered by the system and the baseline delivery rate. These detected events are metrics that provide information relating to the therapeutic value of the system which, without such metrics, may be overlooked or unnoticed, thereby fostering trust and confidence in the delivery system. In addition, information is provided which may enable further improved glucose control.

Claims

1. An insulin delivery system comprising:

a pump that is controllable to adjust insulin delivery relative to a baseline delivery rate;

a sensor for measuring glucose levels of the patient;

a controller coupled to the pump and sensor and configured to calculate insulin delivery based upon an autonomous modulation algorithm utilizing measured signals from the pump and sensor and configured to perform sequential averaging of insulin deliveries made by the system and a scheduled basal rate over a period of time; and

a visualization and analysis tool engageable with the controller, the tool enabling the detection and display of at least one activity event in which the controller compares a scheduled insulin delivery to actual delivery of insulin by the system and determines the presence of the at least one activity event based on periodic sample averaging of both the scheduled and delivered insulin and wherein the at least one activity event is based on a ratio of a system-delivered insulin amount to the corresponding scheduled amount being less than or greater than a therapeutically relevant ratio.

2. The delivery system as recited in claim 1, wherein the at least one activity event is designated as either a hypoglycemic activity event when the ratio of system delivered insulin to the corresponding scheduled amount is less than the therapeutically relevant ratio or a hyperglycemic activity event when the ratio of system-delivered insulin amount is greater than the therapeutically relevant ratio.

3. The delivery system as recited in claim 1, wherein the visualization and analysis tool creates a plot based over an extended period of time in which the frequency of detected activity events is displayed based on the time of day over the extended period of time.

4. The delivery system as recited in claim 3, in which the extended period of time is greater than one week.

5. The delivery system as recited in claim 3, in which the extended period of time is greater than two weeks.

6. The delivery system as recited in claim 3, wherein the extended period of time is selectable.

7. The delivery system as recited in claim 1, in which the delivery of insulin by the controller is governed by model predictive control.

8. The delivery system as recited in claim 1, in which system data is displayed by the tool in at least one tabular format.

9. The delivery system as recited in claim 1, in which the at least one activity event can occur even while glucose levels of a patient as detected by the sensor are still within an acceptable target range.